Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
CA 2470624 A1 · Owner: Wayman, Christopher Peter · Inventors: Baxter, Andrew Douglas; Wong, Stephen Kwok-Fung; Wayman, Christopher Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of a composition comprising a selective dopamine D3 receptor agonist wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay in the preparation , of a medicament for the treatment and/or prevention of sexual dysfunction.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 10, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 10, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 10, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.